FDA inspection
Laurel Regional Hospital: FDA inspection ending Jan 11, 2001
FDA inspection 58491 · No Action Indicated (NAI) · Laurel, MD
Key facts
| Inspection ID | 58491 |
|---|---|
| Firm | Laurel Regional Hospital |
| FEI number | 1177720 |
| Address | 7300 Van Dusen Rd |
| City | Laurel |
| State | MD |
| ZIP | 20707-9463 |
| Fiscal year | 2001 |
| Inspection end date | Jan 11, 2001 |
| Classification | No Action Indicated (NAI) |
| Project area | Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data